The rationale for the use of catecholamines in clinical practice has often been related to their pressor effects. In the early 1950s, when norepinephrine was first used in the treatment of cardiogenic shock, the focus of attention was the arterial blood pressure (Miller & Baker 1952 , Miller et al. 1953 . Indeed, at that time we had little understanding of the complex systemic and cardiac effects of the catecholamines, but we did consider that they might improve blood flow to the intact myocardium.
In the 1960s it was shown that dopamine, the naturally occurring precursor of norepinephrine, had a significant positive inotropic effect on heart muscle, and that its pharmacological properties were different from those of norepinephrine (Holmes & Fowler 1962 , Black & Rolett 1966 , McDonald & Goldberg 1963 , MacCannell 1969 . And, almost predictably, its clinical use was directed primarily to the treatment of cardiogenic shock. This really remains true up till the present time.
Various studies have shown that dopamine increases cardiac output in man by increasing myocardial contractility (Loeb et al. 1971 , Horwitz et al. 1962 , Rosenblum et al. 1972 , McDonald et al. 1964 , and that when the arterial blood pressure rises, this is a function of the positive inotropic effect and the resultant increase in cardiac output (Loeb et al. 1971 , Holzer et al. 1973 . It has been held that dopamine does not generally cause troublesome arrhythmias (Rosenblum et al. 1972 , Holzer et al. 1973 , MacCannell et al. 1966 , and that it gives rise to little or no increase in heart rate (Rosenblum et al. 1972 ). Evidence has been presented that it increases mesenteric blood flow (Eble 1964) and renal blood flow (McDonald et al. 1964 , McNay et al. 1965 ). It has been reported to dilate coronary arteries (Brooks et al. 1967) , and at least one paper suggests that the increased stroke output it produces is achieved at a relatively small metabolic cost (Crexells et al. 1973) .
One could anticipate that these various pharmacological properties of dopamine would make it effective in the treatment of shock, and indeed, its value here has been confirmed (Loeb et al. 1971 , Holzer et al. 1973 , MacCannell et al. 1966 . There is some recent evidence indicating that dopamine does not increase mesenteric blood flow (Pawlik et al. 1976, Hirsch, personal com-munication) , and this controversy will have to be resolved by further data.
The problem is complicated by the fact that cardiogenic shock, at least that true state of shock following acute myocardial infarction which mobilizes the therapeutic ardour of so many of us, has a terrible prognosis no matter what the treatment. Certainly dopamine is an important addition to the pharmacological agents available to treat this condition, but its results are predictably poor. The destroyed myocardium is not restored by any catecholamine. As one would expect, dopamine has been extremely effective in patients who are hypotensive after cardiac surgery, and in helping patients who are coming off cardiopulmonary bypass. I question the practice of some workers of lumping these patients together with those in shock after myocardial infarction. In the postoperative subjects the heart is usually in better condition, and has more potential for effective function, than in patients who have just had an infarct. In our experience with certain high risk patients, the combination of dopamine with intra-aortic balloon pumping is often highly effective, and even life-saving, after cardiac surgery.
The first important data showing that dopamine produced a sodium diuresis in patients with congestive heart failure appeared in 1963 (Goldberg et al. 1963) . It was thought possible that the sodium diuresis was due to renal vascular dilatation (McNay et al. 1965 ). This dopamineinduced renal vasodilatation was considered to be nonadrenergic, because the effect was not blocked by alpha or beta adrenergic blocking agents (Goldberg 1968). The increase in renal blood flow and the overall decrease in systemic vascular resistance made the use of dopamine an attractive proposition for the treatment of congestive heart failure (Goldberg 1968), particularly as it was reported that it hardly ever produced troublesome arrhythmias or tachycardias. Table 1 summarizes the theoretical assets of dopamine in the treatment of congestive heart failure. In spite of this impressive list of qualities, there have been few reports on its actual use in heart failure (McDonald et al. 1964 , Goldberg 1968 , Mac-Cannell 1969 .
In this modern era, the treatment of congestive heart failure generally is quite effective. The potent diuretics available, the better understanding of how to use digitalis products, our ability to control heart rates, and our improved ability to treat ectopic impulse formation have all contributed to this efficacy. It would be ludicrous to suggest dopamine as a 'first line' intervention in the uncomplicated patient with chronic congestive heart failure. However, I believe that Table 1 Reported effects of dopamine pertinent to its use in the treatment of congestive heart failure (1) Increased cardiac output (a) Increased stroke output (b) Increased heart rate (2) Increased urine formation (a) Increased renal blood flow (b) Increased glomerular filtration rate (3) Increased urine sodium excretion (4) Decrease in prerenal azotemia (fall in BUN) (5) Rise in systolic arterial pressure with a fall in diastolic pressure (6) Acts promptly, with clinical evidence ofeffectiveness at low dosage (7) No significant increase in myocardial irritability (8) Compatible with, and possibly synergistic to, action of diuretics (9) Possible dilatation ofcoronary arteries. Possible that increased cardiac output is at relatively small energy cost dopamine does significantly extend our ability to treat chronic heart failure which has not responded to the usual therapeutic measures, and that it may have a role in patients with acute pulmonary cedema who do not recover rapidly on the usual treatments.
At our hospital we have had a relatively modest amount of experience with the use of dopamine in congestive heart failure, but the patients treated have been carefully selected and have all been under close supervision. All were seriously ill and all had received the usual treatment with unsatisfactory responses.
Let me present one patient in some detail and a few others briefly to illustrate some of our experiences with the use of dopamine. The other medications which each patient was receiving were continued. Case 1 PR, a 65-year-old retired car worker, had been hospitalized repeatedly for congestive heart failure due to a cardiomyopathy. He had high degree atrioventricular block requiring a permanent transvenous pacemaker. In the past he had suffered both cerebral and pulmonary emboli. His clinical picture had become that of deteriorating cardiac cachexia. On 12 November 1975, he was admitted to the Nortlhwestern Memorial Hospital with increasing congestive heart failure.
He had marked cedema of the lower extremities, rales at the lung bases bilaterally, shortness of breath on minimal exertion and an apical diastolic gallop. He was intermittently confused, and showed the clinical signs of a 'low cardiac output syndrome'.
By 28 November 1975, he had shown little improvement. His blood urea nitrogen (BUN) varied between 102 and 110 mg/100 ml, with a creatinine of 2.90 mg/100 ml. Serum potassium was 5.3 mEq, chloride 79 mEq, sodium 134 mEq and CO2 27. He had lost no significant amount of oedema fluid after treatment with frusemide, digoxin, isosorbide, nitropaste, allopurinol and potassium supplementation.
On 4 December 1975, a Swan-Ganz catheter was passed. Right ventricular pressure was 50/4 mmHg; pulmonary artery pressure was 50/20 mmHg, and cardiac output by the thermodilution method was 3.8 litres per minute. A pulmonary capillary wedge pressure was 20 mumHg.
The patient's weight at this stage was 122 lb. An infusion of dopamine, 100 jug per minute, was started.
One hour later the cardiac output was 4.35 litres per minute. Occasional ventricular premature beats were seen. Urine output significantly increased. The blood pressure was 100/40 mmHg shortly after dopamine was begun. By 6 December 1975, this had risen to 130/60 and his BUN had fallen to 84 mg/100 ml. A cardiac output determination (thermodilution) with dopamine running at 100 ug per minute was 4.7 litres per minute. Lidocaine was used intermittently to treat ventricular premature beats, which became frequent at times. On 10 December 1975, dopamine treatment was stopped. The patient's weight had dropped to 116 pounds, and he showed significant loss of cedema. His appetite and affect were both improved. The BUN was down to 68 mg/100 ml. His blood pressure was 1 6/68 mmHg.
The patient was discharged from hospital on 19 December 1975, having shown significant improvement.
Case 2 FS, a 54-year-old sanitary district worker with diabetes was admitted to the Northwestern Memorial Hospital on 7 January 1976. This was his second hospital admission, now with the clinical picture of severe congestive heart failure. Cardiac catheterization studies supported the clinical diagnosis of congestive cardiomyopathy. His coronary arteries were quite normal, and no etiology was found for his marked cardiomegaly.
At the time of hospital admission his weight was 252 pounds. His blood pressure was 130/90 mmHg. There was marked foot, ankle and leg cedema. He was orthopnceic, with some shortness of breath at rest in the sitting position, and rales were heard at both lung bases posteriorly. The liver was palpable 5 cm below the right costal margin. An S3 was heard at the cardiac apex.
Treatment was instituted with digoxin, a sodiumrestricted diet, triamterene and furosemide. His diabetes mellitus was treated with lente insulin. Increasing dosages of furosemide resulted only in slow diuresis, with no improvement in his symptoms. Blood pressures varied between 110/80 and 90/70 mmHg. The BUN was 25 mg/100 ml, sodium 138 mEq, potassium 316 mEq, chloride 96 mEq. A hiemoglobin was 14.7 gm; the hvmatocrit was 47%.
Frequent ventricular premature beats were treated with procainamide. A repeat BUN was 27 mg/100 ml.
On 18 January he was started on dopamine at a rate of 100 ztg per minute, which was soon increased to 150 ,tg per minute. His heart rate increased to 110 beats per minute when the dopamine was increased to the maximum dosage he received, 250 Hg per minute, and he had some sensation of his heart pounding. The ventricular premature beats were generally less frequent than before he started the dopamine therapy. On 20 January his BUN was 18 mg/100 mil.
His weight fell steadily on continuous dopamine therapy for four days. During this time his other medications were continued unchanged, as they were after dopamine was stopped. At the time of hospital discharge his weight was 200 pounds, he was cedemafree, without shortness of breath, and he again had a good appetite.
Three weeks after hospital discharge he had gained five pounds and was feeling well. Physical examination revealed no evidence of fluid retention. Four months later he had gained a total of eight pounds from the time of hospital dischalge, he was feeling well, and was working regulaily at his undemanding desk job.
Case 3 JS, a 69-year-old man with a history of a previous massive myocardial infarction, was seen with progressive congestive heart failure and poor response to treatment with the usual medications.
He showed Cheyne-Stokes respiration, blunted intellectual reactions, with recurrent stupor, and recurrent pulmonary cedema. His blood pressure was 110/70 mmHG; and heart rate was 100 beats/min.
He was started on dopamine 225 ug per minute on 19 May 1975. Prior to that time his BUN varied between 31 and 34 mg/100 ml, and creatinine between 1.79 and 2.04 mg/100 ml; his serum sodium was 133 mEq. Central venous pressure was stable at 18 mmHg.
On 20 May he had an increased urine output and the central venous pressure was down to 12 mmHg. He had a sinus tachycardia of 105 beats per minute.
At 5.00 a.m. on 20 May the dopamine was suddenly stopped at a time when the patient's general condition was improved. He quickly became short of breath and tachypnceic, and his skin felt clammy. The dopamine was restarted at 8.30 a.m., after which his clinical state improved and the urine output increased. His blood pressure was 94/70 mmHg at that time.
At 2.30 p.m. on 20 May the dopamine was again stopped, and again his general condition appeared to deteriorate. A Swan-Ganz catheter was passed at 4.00 p.m., and the dopamine was restarted at 150 ,zg per minute. He became more alert, the central venous pressure varied between 8 and 12 mmHg, and his urine output increased. The Cheyne-Stokes respiration ceased. He was continued on dopamine until 24 May, at which time his blood pressure was 120/ 70 mmHg. He was clinically improved, and his weight had fallen from 169 to 160 pounds. His BUN was 31 mg/100 ml, and his serum sodium was 135 mEq.
Case 4 BH, a 72-year-old woman, was admitted to the Northwestern Memorial Hospital with the picture of cardiac cachexia on 29 March 1976. Her admission weight of 71 pounds did not change until 16 April, when it was 75 pounds and she showed evidence of fluid retention with cedema of the feet and ankles and more rales in the chest. On the next day she was gravely ill with increasing shortness of breath, hypotension, with blood pressures varying between 60/50 and 70/50 mmHg, increasing peripheral cedema, vomiting and pallor. Her BUN was 82, creatinine 1.56, uric acid 11.2 mg/100 ml. Serum sodium was 131, potassium 5.3, chloride 96 mEq; bicarbonate 21. The hlimatocrit was 29 %.
The patient was known to have longstanding valvular heart disease, with aortic stenosis and insufficiency and mitral insufficiency. The picture was further complicated by a recent myocardial infarction, with a rise in CPK isoenzymes to 36%.
On the morning of 17 April she was transferred to the coronary care unit, a Swan-Ganz catheter was passed, and she was started on dopamine at a rate of 50 ,ug per minute. The pulmonary artery pressure was 75/28 mmHg, with a mean pressure of46. A pulmonary capillary wedge pressure was read as 36 mmHg, with tall V waves present. A repeat pulmonary artery pressure shortly after the dopamine was begun was 75/24 mmHg. A repeat BUN was 83 mg/100 ml. The mean arterial pressure rose to 75 mmHg, the heart rate increased to 100 beats per minute, and the patient showed clinical improvement.
The rate of dopamine infusion was increased to 75 ug per minute. Her mean arterial pressure varied around 68 mmHg, and her heart rate varied between 100 and 110 beats per minute. The pulmonary diastolic pressure remained at a mean of 25 mmHg. She became less short of breath, but ventricular premature beats occurred at 8 to 10 per minute. The dopamine was decreased to 62.5 /tg per minute. Her condition remained fairly stable on 18 April. On 19 April her mean arterial pressure was 64 mmHg, and central venous pressure varied between 6 and 12 mmHg. An adequate urine output seemed to depend on the rate of dopamine infusion. Her weight came down to 72 pounds and the BUN fell to 74 mg/100 ml. Her heart rate varied between 100 and 120 beats per minute, with some further increase in ventricular premature beats. She was started on oral procainamide, and the dopamine infusion was maintained at 62.5 ,g per minute.
On 20 April the dopamine infusion rate was decreased to 50 ug per minute. She showed only rare ventricular premature beats. The BUN was 68 mg/ 100 ml, her urine output increased to as high as 70 ml per hour, and the mean arterial pressure was around 80 mmHg. The dopamine infusion rate was decreased to 37.5 Hg per minute.
On 21 April her urine output varied between 30 and 50 ml per hour, with dopamine at a rate of 37.5 ug per minute. Her heart rate varied around 100 beats per minute. On 22 April the dopamine infusion rate was decreased to 25 ,ug per minute, and her condition continued to improve. Her BUN fell to 55 mg/100 ml and her creatinine was 0.90 mg/100 ml. Dopamine was discontinued, after which her heart rate slowed to between 90 and 96 beats per minute. No ventricular premature beats were seen after dopamine was discontinued.
Other therapy which was continued during the period of time that she received dopamine included nitropaste, digoxin, diazepam, sublingual nitroglycerine, and procainamide.
Two days after dopamine was discontinued her BUN was 70, creatinine 1.56 mg/100 ml.
Case 5 SL, a 69-year-old male retired factory worker, was admitted to the Northwestern Memorial Hospital on 22 May, with the clinical picture of severe congestive heart failure. Previous cardiac catheterization studies had revealed severe coronary atherosclerosis and a ventricular aneurysm, which were not considered to be operable In 1973 recurrent pulmonary emboli were successfully treated by the placement of an inferior vena cava 'umbrella' prosthesis.
At the time of hospital admission his weight was 142 pounds. Blood pressure was 100/90 mmHg, BUN was 51, creatinine 2.10 mg/100 ml. A chest X-ray revealed congestion and pleural effusion.
On 25 May his BUN was 66 and the creatinine was 1.98 mg/100 ml. On 2 May his weight had fallen to 140 pounds with diuretics, but he still had severe cedema of the feet and ankles.
On 30 May his blood pressure was 120/96 mmHg, and his pulse rate 112 beats per minute. Marked aedema of the feet and ankles persisted. The patient was started on dopamine at a rate of 350 Ftg per minute; this was soon decreased to 250 jug per minute. His urine output dramatically increased to 350 ml of urine in the first four hours of treatment. His blood pressure was 116/82 mmHg and his heart rate was 114 beats per minute. On the next day his weight was down to 135 pounds, his heart rate was 118 beats per minute, and the nurses described the patient as 'more comfortable'.
On 1 June the rate of dopamine infusion was decreased from 200 to 150 zg per minute. His hearf rate wa6 130 beats per minute and his blood pressure was 110/70 mmHg. It was noted that his previously persistent Cheyne-Stokes respiration now disappeared for short periods of time. On 2 June he was described as 'alert'. Dopamine was stopped on June 3, after its rate of administration had been reduced to 100 jg per minute. The patient's weight had fallen to 134 pounds.
The clinical progress of these 5 patients is summarized in Table 2 .
We have also treated 2 patients with pulmonary cedema. One was a 62-year-old woman with cardiac cachexia on the basis of severe rheumatic mitral valve disease. She developed acute pulmonary aedema after blood transfusion, and did not respond well to intravenous digoxin and frusemide. Dopamine produced a prompt clinical improvement, with clearing of lung rales and a diuresis. However, lidocaine had to be used to control ectopic beats. The other, a 69-year-old woman, sustained an acute myocardial infarct, and went into pulmonary cedema. The response to intravenous frusemide was unsatisfactory, but dopamine led to rapid improvement, with clearing of lung rales and a moderate diuresis. The improvement was transient, and the patient died four hours later in cardiac asystole.
In 1963, Goldberg, McDonald & Zimmerman reported careful studies of dopamine treatment in four patients in congestive heart failure, and found a significant sodium diuresis together with clinical improvement. Subsequently, Goldberg (1968) summarized their group's experience in the treatment of 11 patients in congestive heart failure with dopamine, and emphasized that sodium excretion increased in all of them. They gave dopamine infusions for up to six hours. More recently Beregovich and his co-workers have studied the effects of dopamine admini- stered for one and a half hours in nine patients with congestive heart failure. The clinical results of this short-term therapy were good, and they concluded that there may be an important role for dopamine in the management of heart failure. Rosenblum, Tai & Lawson (1972) studied 12 patients in chronic heart failure during cardiac catheterization. They found an increase in cardiac output, an increased sodium excretion, and little change in heart rate. The maximum period for which they administered dopamine was 89 minutes. How well has the promise of dopamine held up in the treatment of congestive heart failure? If we look at Table 1 again, it would appear that it does for the most part measure up quite well. It produces improvement in the clinical picture, there is an added diuresis, prerenal azotemia is lessened, and there is direct and indirect evidence of improvement in cardiac output. At times the heart rate does increase quite a lot. But in the treatment of heart failure this is not necessarily a disadvantage. After all, increasing the heart rate is often an effective means of increasing the cardiac output. More important, however, is the fact that dopamine not infrequently causes ventricular premature beats, which at times require treatment. Thus, at least under ideal circumstances, it appears desirable to monitor heart rhythm in patients receiving dopamine. In spite of this problem we have found that continuous dopamine infusions can be given safely for up to seven days. Dopamine proved to be relatively easy to use. When it caused ventricular ectopic beats these responded promptly to treatment with lidocaine or procainamide. The dosages of dopamine which proved clinically effective were at times surprisingly small.
It was of particular interest that two of the patients we treated had long-term remissions in their state of chronic congestive heart failure. Both were patients with cardiomyopathy, in whom clinical improvement persisted for three and four months respectively. Perhaps we should not be surprised at such an observation; after all, we know that patients in congestive heart failure will improve for significant periods of time after treatment with a sufficient period of bedrest.
We can conclude, I believe, that dopamine has an important role in the treatment of severe chronic congestive heart failure, and that treatment with low doses is often efficacious. It may well prove to be of value in the treatment of acute pulmonary oedema. Because these patients with heart failure seem to be susceptible to ventricular ectopic beats with dopamine treatment, heart rhythms should be monitored and arrhythmias appropriately treated. 
DISCUSSION
Professor Dollery (Chairman): Dr Miller, you began by saying that if there was no myocardium left after myocardial infarction then dopamine could not do very much. I wondered if the same was not really true in some of these people with very severe congestive heart failure, in whom the myocardium, or the mechanical state of the heart, is severely damaged. Because in fact in only one or two of the patients that you presented was there a really impressive change; in the others, although there was a small fall in the BUN, the serum creatinine did not changethat could have been a dietary effect, I supposeand the weight losses were only of the order of 4 or 5 lbs, which was not very dramatic. I think the patients responses were much greater than that, but the general impression was not very dramatic.
Dr Miller: I think, first of all, that we have to start off with the fact that there is a difference between the patient who has had an acute myocardial infarction and is in cardiogenic shock due to myocardial infarction, and the patient who presents in intractable congestive heart failure. Most of the patients that we see in socalled intractable congestive heart failure are, indeed, treatable. The intractability is often a function of inadequate therapy.
In these 5 patients treatment had been vigorous by acceptable clinical yardsticks, and they had not adequately responded. It is true that the figures for some of these patients are not dramatic. Weight loss of 5 pounds in a patient with intractable congestive heart failure is in itself perhaps not a dramatic finding. Actually in these 5 patients the clinical improvement was really quite striking.
The two patients with cardiomyopathies had much more edema. I think these were the ones who showed the more dramatic results, because they lost so much more weight.
I am by no means suggesting that dopamine is the end-all for the treatment of congestive heart failure; but if you recall, in the early days of norepinephrine there were some people who thought that norepinephrine might be of value in the treatment of congestive heart failure. There were reports at that time that it increased renal blood flow under certain circumstances and that urine output increased. What I am suggesting is that there are a certain number of patients who present with intractable failure, who have a decreased cardiac output, with or without significant cedema, and who will improve with longterm dopamine therapy. In one of these cases I think it allowed us to get the patient over a hump and, finally, to transfer him to the surgeon who could replace the valves that needed replacing.
Professor Goldberg: That is essentially the kind of patient that we have seen respond. It is interesting to me that, once these refractory patients have a diuresis, they seem to go for a considerable period of time before they get cedema again.
The question I have is this: the vogue in America is for using after-load reduction or preload reduction with sodium nitroprusside, and we are trying to work out which of these refractory patients should receive dopamine. I just wonder whether you have any comments, and then perhaps I can tell you what conclusions we have come to.
Dr Miller: Well, that is a good question and, as you know, everybody is confused about this. At least one group in the United States which strongly supports the concept of nitroprusside unloading of the left ventricle in intractable heart failure is now adding dopamine to the treatment in some of their patients. So they are using nitroprusside combined with dopamine.
Our own experience with nitroprusside at Northwestern is vast. This is mainly because our anesthesiologists use nitroprusside hypotensive anmsthesia, and they find this very suitable in patients who have essentially normal coronary arteries. I think that we are far from the answers on how to proceed in patients with failure and I should be interested to know your views.
I was going to ask the clinical pharmacologists a question, so let me take advantage of being up here to do that. One pharmacologist mentioned to me, when I was talking to him about the fact that a couple of heart failure patients we treated with dopamine seemed to persist in their improvement (apparently this is your experience, too), that intermittent treatment of such patients perhaps for a couple of days once a month might be of value. The question is whether there may be something here that really is different from just bed rest. It may be that something is changing.
Professor Goldberg: I do not know whether there is something unusual about dopamine or not. I think it is simply starting the diuresis; that is my guess. Once the heart gets smaller it does well, however you achieve this. Some patients respond to furosemide and then do well for a long period of time. But what we are trying to find out is when to use nitroprusside and when to use dopamine. If you use nitroprusside and perfusion pressure drops, and there is a chance of coronary ischmmia, then I think you had better stop. Then we try dopamine. Ifdoparnine increases peripheral resistance, that is bad. You are working on a very fine knife edge. So what we generally do, if a patient's pressure is high, is to start with nitro-prusside and see what happens. Frequently the cardiac output goes up dramatically and they respond, but if the pressure drops too much, then we may switch to dopamine. We also use the two together. I think they may be pretty good together because the nitroprusside blocks some of the vasoconstriction of dopamine and also dilates the venous bed like an internal tourniquet. I think most of us have found that once a patient like this has a diuresis, however he achieves it, he does well for a certain period of time until the heart gets big again. I think it is simply putting the heart on a better Starling curve.
I might mention a few words of caution. We always start with a very small dose of dopamine, because if you increase peripheral resistance and increase after-load then it may be detrimental. So we start with about 0.55,g/kg per min, gradually go up to 1.0, then very gradually go up further until we get a diuresis; at that point we cut back, continuing careful observation. Of course, we are very careful to avoid ventricular ectopic activity.
The other thing that we noticed in a couple of patients was angina pectoris. This is another reason for being very cautious about the afterload. One has to proceed very cautiously, but we have given dopamine for three weeks at a very slow rate in one case. This particular patient left the hospital, and he is still doing well.
Dr Miller: Our experience also is that patients who are hypertensivefor example, the patient who has had an acute myocardial infarction and comes in to the hospital with a raised blood pressure will do very well with nitroprusside.
Professor Dollery: Did Dr Goldberg make any controlled observations? Did he have a control series? Because, when we were considering some studies with dobutamine and wanted to do work in patients of this kind, we looked at the Hammersmith to find how many patients there were, and we found there really were very few who would fulfil the necessary criteriain whom one might want to use the drug and who were suitable to go into a clinical trial. In fact, we abandoned it for that reason. It is very difficult to get many patients to study. The thing that persuaded us that we would have to have a control group was that these patients with severe congestive failure often did improve rather dramatically just with bed rest. That is why I personally would be sceptical of observations which are not controlled. Was there any control group?
Professor Goldberg: This is not very difficult to do in our studies. We had a long control period before treatment, and dopamine acts quickly. In that patient I showed, you will remember there were 7 days during which he was excreting 0.3 mEq of sodium per 24 hours. He was in the hospital for three weeks and then there was one week when he had a metabolic balance study. Then we gave dopamine and, within 10 minutes, he was having a diuresis. It is a rapid phenomenon. So one does not have to have a long control period to see a hxemodynamic effect develop. That patient was in the hospital for three weeks.
Professor Dollery: You must make a distinction, presumably, between a number of objectives. If the objective is primarily to produce this sodium diuresis acutely, then I accept of course that what you say is correct. If your primary aim is to improve cardiac output, tissue perfusion and the patient's wellbeing, perhaps it is a more difficult matter to assess.
Professor Goldberg: If one gets a diuiresis with furosemide, then the patient's heart becomes smaller and it becomes more efficient. We know that, in a large heart, by La Place's law, the radius of the heart is large, it uses more oxygen and it is less efficient. So a simple diuresis has been shown many times to improve cardiac function, and cardiac output will increase simply by decreasing the pre-load. So that a diuresis itself is very useful. I see dopamine in acute pulmonary adema as acting like aminophylline, which a lot of us use. I might say that we had some interesting experiences with acute pulmonary cedema. I remember the first time we tried dopamine was in a patient who was a compulsive salt eater. He would come into the hospital repeatedly with pulmonary cedema. I was listening to his chest and my colleague was starting the intravenous drip. I said, 'He's better, he's better, he's better', and he said, 'I haven't started the dopamine yet'. So, you know, with acute pulmonary cedema it is just reassurance sometimes. Dr Miller: I should like to comment on that though. I think that this particular kind of patient is not common in our institution either. Obviously we do not have a series of 20 patients. But I also agree that it is extremely difficult to get what you would call a control group. I think that if we tried to figure out a control group based upon treatment versus non-treatment there would be great flaws in trying to define an adequate control group. The question here is whether the patient's status prior to the time of treatment represents an adequate control period. I think that that is the critical question. I believe that the answer is 'Yes', but it is certainly debatable.
In the area of acute pulmonary cedema, I should like to speak as a clinical cardiologist for a moment. Certainly, treating two patients is no basis from which to make broad generalizations. However, anybody who cares for patients has seen that type of acute pulmonary cedema which just does not respond to the usual treatments, that is oxygen, intravenous furosemide, intravenous digitalization, and so on. We then have a patient who is desperately sick. That was the kind of situation where we gave the dopamine, and those two patients showed a dramatic and prompt response. I am not saying that they might not have responded just as well to unloading the left ventricle with intravenous nitroprusside, but the point is that we have to think about dopamine as a relatively heroic measure.
Dr Zaroslinski: I wonder whether Dr Miller might comment on his experience with other patients with reference to the effects on heart rate. This goes back to the point made by Professor Dollery about the extent of myocardial damage. We found, in analysing the data on the multiclinic trials, that the patients who survived appeared to have cardiac slowing, which we felt was a compensatory mechanism resulting from an improved cardiac output. I wonder whether you may have observed a similar type of response in other categories of patients, because in your congestive failure group you seemed to have either a constant heart rate or an increase. Dr Miller: Our experience in patients with congestive heart failure is not enough for me to answer that question. I do not know. I think it probably makes a certain amount of sense, but if a patient who is in congestive heart failure is mobilizing tachycardia as a means of maintaining cardiac output, and if with treatment he tends to slow that heart rate, they may represent a good prognostic sign.
My own experience in the treatment of cardiogenic shock, where we have pretty much followed the kind of protocol suggested by Dr Goldberg, and tailor-make the catecholamine administration to the circumstances, is that our results are usually poor irrespective of the drug used. As a purely subjective response, I feel more comfortable using dopamine in congestive heart failure, which you will recall was the original suggestion of Dr Goldberg and his group, than I do in trying to treat cardiogenic shock.
Mr D Longmore (London): I was very interested in Dr Miller's presentation, particularly in his slide which showed changes in the efficiency of the heart -I forget how it was worded. It seems to me, having the advantage of not having used dopamine so far and, therefore, being an instant expert on it, that the thing that we really want to know is whether the increase in cardiac output is paid for by an enormous price in myocardial oxygen consumption, or whether it is an economic method of increasing cardiac output.
We are trying to check this by measuring myocardial oxygen consumption in patients in the intensive care unit, and it is extremely difficult to do. However, it is quite easy to increase a patient's cardiac output by 10% and increase myocardial oxygen consumption by 200 %. Where does dopamine come in this league of catecholaminelike drugs ?
Dr Miller: That is a fine question and I should like to defer to my clinical pharmacologist friends. I think that Dr Goldberg can probably answer that better than I can.
Professor Goldberg: You know, you do not get anything for nothing. It used to be thought that digitalis did not waste oxygen, but this is, of course, wrong. The reason why we had the courage to use dopamine at all was simply La Place's law: if one increases cardiac output without changing heart rate very much, and with no increase in peripheral resistance, and if the heart becomes smaller, then it is not wasting oxygen. If the heart becomes larger or does not change in size, then oxygen is wasted. If you give digitalis to a patient with a big heart, the cardiac output goes up and the rate is slowed, and the oxygen consumption decreases. A group in Montreal (Crexells et al. 1973, Cardiovascular Research 7, 438 ) did in fact measure oxygen consumption in patients with coronary heart disease who were given dopamine and it did not increase.
The only way I can possibly explain this is that the heart became smaller. I do not know any other way to explain it, because a positive inotropic effect has got to use oxygen. If one studies things which increase oxygen consumption, they are ranked in this order. The greatest waster of oxygen is increased peripheral resistance or increased after-load, which makes the heart bigger. For example, if you give methoxamine or angiotensin, which have no positive inotropic effect, oxygen is wasted because the heart gets bigger. If you just increase the rate, more oxygen is wasted than with a positive inotropic effect. Lastly, there is the positive inotropic effect itself, which certainly wastes oxygen. So I do not know how one could tell in an individual patient. I do not think that there is going to be a magic positive inotropic drug. This, of course, underlies the controversy about nitioprusside versus positive inotropic drugs. I think that it has swung a little bit too far the other way. That is, everybody is using after-load reduction, but if one decreases after-load and decreases perfusion pressure one can be in trouble.
I consider it a very fine knife-edge, and I do not know anything one can do except observe a patient very carefully clinically. Dopamine, of course, can produce arrhythmias; any inotropic drug can, particularly in the hypoxic myocardium. So I think that it has to be done very carefully and, hopefully, if digitalis works then a drug like this should do the same. That at least has been my thinking.
Professor Dollery: What happens to the whole body metabolic rate when you infuse dopamine?
Professor Goldberg: It does not increase. Dopamine has much less metabolic stimulating action than, say, epinephrine. Epinephrine is number one in that area and dopamine is number three, say, after norepinephrine. I am very concerned about infusing dopamine very slowly and being very careful not to let after-load increase very much. This, I think, would be the biggest danger in treating congestive heart failure with dopamine.
Dr A Bennett (London): This question of controls is very important, and should not be skipped over too lightly. I think it is probably easier to achieve than has been suggested. For example, you can first infuse the vehicle alone and see what happens to the patient, and then you can administer dopamine. When the response comes back to base line again give the vehicle alone.
Professor Goldberg: We always did that (see Fig 2 on page 8 ).
Dr Bennett: In other words, you undervalued your data when you said there were no controls.
Dr Miller: I think we have to emphasize that we need much more study of the use of dopamine in the treatment of congestive heart failure.
